Clinical Trial: Comparative Efficacy and Safety if Intravesical Botulinum Toxin A Versus Platelet-Rich Plasma in the Management of Refractory Overactive Bladder : A 2 Year Study

U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07693192) titled 'Comparative Efficacy and Safety if Intravesical Botulinum Toxin A Versus Platelet-Rich Plasma in the Management of Refractory Overactive Bladder : A 2 Year Study' on July 03.

Brief Summary: The goal of this clinical trial is to compare the efficacy and safety of intravesical Botulinum Toxin A versus intravesical Platelet-Rich Plasma (PRP) in adults with refractory overactive bladder who have not responded adequately to conventional medical treatment. The main questions it aims to answer are:

* Whether intravesical PRP is as effective as intravesical Botulinum Toxin A in improving overactive bladder symptoms.

* Whether intravesical...